PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Comparative Safety Signals for Melanoma Checkpoint Inhibitors Across Trials and FAERS

pembrolizumabnivolumabipilimumabatezolizumabspartalizumabimmune checkpoint inhibitorsmelanomaimmune-related adverse eventspharmacovigilanceFAERSnetwork meta-analysis Oncology

Background Information

Immune checkpoint inhibitors in melanoma: safety profiles unveiled.

Understanding the safety profile of immune checkpoint inhibitors (ICIs) for melanoma is crucial as these treatments carry risks of treatment-related and immune-related adverse events. In a network meta-analysis of 31 randomized controlled trials with 11,937 patients, ipilimumab, nivolumab, and pembrolizumab showed the lowest risk for adverse events, while chemotherapy had lower immune-related adverse events. The study provides valuable data for monitoring and assessing risks of adverse events in melanoma patients on ICIs, but it should not be taken as prescribing guidance. ICIs for melanoma have varying safety profiles, highlighting the need for careful monitoring.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chen Y, Liang X, Chen X, Li Y

Citation: Chen Y, Liang X, Chen X, et al. The Real-World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence. Health science reports. 2026;9(8):e72865. doi:10.1002/hsr2.72865

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.